Kodiak Sciences
KOD | NASDAQ
$100.73
-$10.46 (-9.41%)
At close: Nov 16, 2026, 4:00 PM ET
$100.73
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:58 PM ET
Kodiak Sciences Company Profile
Company profile explainedCompany Profile
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Key Executives
| Name | Position |
|---|---|
| Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President |
| John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary |
| Wayne To | Chief Technology Officer |
| Almas Qudrat | Chief Quality Officer |
| Dolly S. Chang | Chief Scientific Officer |
| Hong Liang | Senior Vice President of Development |
| J. Pablo Velazquez-Martin | Chief Medical Officer |
| Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 4 | Filing |
| Oct 23, 2026 | 4 | Filing |
| Oct 20, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Sep 30, 2026 | SC 13D/A | [Amend] Filing |
| Sep 30, 2026 | 4 | Filing |
| Sep 30, 2026 | 4 | Filing |
| Sep 30, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Kodiak Sciences
| Country | United States |
| IPO Date | Oct 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Victor Perlroth |
Contact Details
1200 Page Mill Road Palo Alto,
California 94304 United States
Stock Details
| Ticker Symbol | KOD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001468748 |
| CUSIP Number | 50015M109 |
| ISIN Number | US50015M1099 |
| SIC Code | 2836 |
Recent News
- 3 days ago / seekingalpha.comKodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In
- 3 days ago / zacks.comKodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
- 4 days ago / prnewswire.comKodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
- 5 days ago / prnewswire.comKodiak Sciences to Present at Three Upcoming Investor Conferences
- 29 days ago / zacks.comCan Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
- 1 month ago / prnewswire.comKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
- 2 months ago / 247wallst.comA $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
- 2 months ago / zacks.comKOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
- 2 months ago / fool.comWhy Kodiak Sciences Skyrocketed Today
- 2 months ago / seekingalpha.comKodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Add to Watchlist
Select watchlists to add or remove KOD